Seattle Genetics (SGEN) Misses Q2 EPS by 12c, Offers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cowen Raises Price Target on Seattle Genetics (SGEN) Following 2Q15
July 31, 2015 8:46 AM EDTCowen reiterated a Market Perform rating on Seattle Genetics (NASDAQ: SGEN), and raises the price target to $40.50 (from $34.00), following 2Q15 results. SGEN posted Adcetris sales of $55.1M for 2Q15, ahead of consensus $50.9M estimates.
Analyst Boris Peaker commented, "SGEN reported 2Q15... More
